| 000 | 01812 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515224045.0 | ||
| 264 | 0 | _c20110801 | |
| 008 | 201108s 0 0 eng d | ||
| 022 | _a1573-7217 | ||
| 024 | 7 |
_a10.1007/s10549-010-0940-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRodríguez-González, F Germán | |
| 245 | 0 | 0 |
_aMicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. _h[electronic resource] |
| 260 |
_bBreast cancer research and treatment _cMay 2011 |
||
| 300 |
_a43-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aBreast Neoplasms _xdiagnosis |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Profiling |
| 650 | 0 | 4 | _aGene Expression Regulation, Neoplastic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aMicroRNAs _xgenetics |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 |
_aReceptors, Estrogen _xmetabolism |
| 650 | 0 | 4 |
_aSelective Estrogen Receptor Modulators _xtherapeutic use |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aTamoxifen _xtherapeutic use |
| 700 | 1 | _aSieuwerts, Anieta M | |
| 700 | 1 | _aSmid, Marcel | |
| 700 | 1 | _aLook, Maxime P | |
| 700 | 1 | _aMeijer-van Gelder, Marion E | |
| 700 | 1 | _ade Weerd, Vanja | |
| 700 | 1 | _aSleijfer, Stefan | |
| 700 | 1 | _aMartens, John W M | |
| 700 | 1 | _aFoekens, John A | |
| 773 | 0 |
_tBreast cancer research and treatment _gvol. 127 _gno. 1 _gp. 43-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10549-010-0940-x _zAvailable from publisher's website |
| 999 |
_c19843924 _d19843924 |
||